Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Moderna Stock: Bull vs. Bear

TheMotleyFool

0 0

There's good news and bad news for Moderna (NASDAQ: MRNA) investors. The good news is that shares of the messenger RNA (mRNA) vaccine maker have skyrocketed over 1,100% since the beginning of 2020. The bad news is that Moderna has given up a lot of its gains with the stock plunging close to 50% below its high from earlier this year.

But is this beaten-down vaccine stock a buy now? Two Motley Fool contributors have different takes on Moderna.

Image source: Getty Images.

Source Fool.com

Like: 0

MRNA

Share